Welcome to our dedicated page for Celularity news (Ticker: CELUW), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Overview of Celularity Inc
Celularity Inc (symbol: CELUW) is a clinical-stage biotechnology company specializing in the development and commercialization of placental-derived cell therapies and advanced biomaterial products. With a robust focus on cell therapy, regenerative medicine, and advanced biomaterials, the company harnesses unique biological properties derived from the postpartum placenta to create off‑the‑shelf allogeneic cell therapies. These therapies include genetically modified and unmodified natural killer (NK) cells, engineered T-cells such as CAR-T cells, and mesenchymal-like adherent stromal cells (MLASCs).
Business Segments and Core Operations
Celularity organizes its operations into three distinct business segments that underscore its multifaceted approach to address significant unmet medical needs:
- Cell Therapy: Focused on delivering innovative allogeneic therapies, this segment develops off-the-shelf cell products targeting a range of indications including various cancers and immunologic disorders. The use of advanced genetic modification techniques and a universal receptor approach allows for the combination of cell therapies with approved antibody treatments, thus presenting a novel modality to overcome challenges associated with traditional therapies.
- Degenerative Disease: This segment is dedicated to using placental-derived cellular therapies to address aging-related and degenerative diseases. The therapeutic programs in this area harness the regenerative potential of MLASCs and engineered immune cells to target conditions that result from the progressive deterioration of tissue function and structure.
- Bio-banking: Serving as a critical source of revenue and operational support, the bio-banking segment capitalizes on the unique, ready availability of placental tissue. By establishing a repository of high-quality biological materials, Celularity supports both its internal therapeutic development and potential external applications, reinforcing its reputation in the field of regenerative medicine.
Innovative Approaches and Technological Edge
At the forefront of Celularity’s innovation is its application of cutting-edge cell engineering techniques. The company’s universal receptor platform enables the modification of T-cells to express proprietary receptors such as CD16, which are designed to interact synergistically with various monoclonal antibodies. This methodology addresses challenges like antigen escape and improves treatment tolerability, particularly in hard-to-treat cancers and immunologic disorders.
Market Position and Industry Relevance
Celularity has established itself as a prominent player in the regenerative and cellular medicine landscape by integrating advanced biomaterial technologies with targeted cell therapies. Its strategic positioning through multiple business segments—including a revenue-strong bio-banking unit—demonstrates a comprehensive approach to meet global healthcare challenges. The breadth of its therapeutic programs, which span cancer, immune disorders, infectious diseases, and degenerative conditions, highlights its commitment to addressing complex medical conditions using scientifically validated methods.
Scientific and Operational Expertise
Underpinned by rigorous research and a well-established manufacturing infrastructure, Celularity’s operations reflect deep domain expertise and regulatory diligence. The company emphasizes robust clinical evaluations, in vivo preclinical studies, and strategic collaborations with scientific experts to validate its therapies. This meticulous approach ensures that each therapeutic candidate, whether in cell therapy or regenerative biomaterials, is developed with a high degree of precision and commitment to quality.
Investor and Researcher Insights
For investors and industry analysts, understanding Celularity’s multifaceted business model is crucial. The company bridges the gap between advanced scientific innovation and commercial viability through its three-pronged operational strategy. By combining innovative cell therapies with an efficient bio-banking process and a focus on degenerative disease treatments, Celularity creates a diversified portfolio that is well-positioned within the broader biotechnology and regenerative medicine sectors.
This detailed overview of Celularity Inc provides a comprehensive insight into how the integration of advanced cellular technologies and bio-based materials is revolutionizing therapeutic approaches. The company’s scientific rigor, combined with its operational efficiency and diversified business segments, underscores a commitment to addressing some of the most challenging conditions in modern medicine.
Celularity (NASDAQ: CELU) welcomes the Centers for Medicare & Medicaid Services (CMS) decision to delay the effective date of a Medicare Local Coverage Determination (LCD) for skin substitute products to January 1, 2026. The LCD, originally published in November 2024, concerns skin substitute grafts and cellular products used to treat diabetic foot ulcers and venous leg ulcers.
The delay follows President Trump's January 2025 executive order freezing regulatory guidance not yet in effect. Initially postponed from February 12, 2025, to April 13, 2025, CMS has now further extended the implementation date. This action, led by CMS Administrator Dr. Mehmet Oz, aims to ensure continued Medicare patient access to critical wound care products while allowing time for comprehensive payment system reform.
Celularity (NASDAQ: CELU) announced a publication in Frontiers in Immunology on April 4, 2025, focusing on the relationship between senescence, Natural Killer (NK) cells, and cancer. The publication explores how aging affects the immune system's fight against cancer and highlights the role of senoablative NK cells in disease progression.
The research emphasizes the importance of maintaining NK cell function for healthy aging and discusses the potential of adoptive NK cell therapy to counter immunosenescence. The company's clinical-stage candidate CYNK-001, a placental-derived allogeneic NK cell therapy, has been studied in over 70 subjects with acceptable safety profiles. The therapy aims to eliminate senescent cells that release toxic cytokines promoting inflammation and malignant transformation, potentially benefiting conditions like age-related frailty and sarcopenia.
Celularity Inc. (Nasdaq: CELU) has received recommendation letters from the FDA Tissue Reference Group confirming that its Natalin and Acelagraft™ wound care products meet criteria to be regulated solely under section 361 of the PHS Act as human cell, tissue and cellular and tissue-based products (HCT/P).
Natalin is a decellularized dehydrated amnion derived tri-layer graft, while Acelagraft™ is a decellularized dehydrated amnion derived bi-layer graft. Both products are indicated for use in partial and full thickness acute and chronic wounds.
According to Nova One Advisor, the global Biological Skin Substitutes market was valued at $347.75 million in 2024 and is projected to grow at a CAGR of 8.83% through 2034, reaching $810.50 million. The chronic wounds segment is expected to grow fastest at 9.13% CAGR, with North America representing 42% of the global market.
Celularity (NASDAQ: CELU) has entered into a Master Services Collaboration Agreement with BlueSphere Bio (BSB) for manufacturing BSB's cell therapy products. This marks Celularity's second such collaboration, showcasing its ability to leverage its cGMP manufacturing infrastructure.
The collaboration will initially focus on producing BSB's novel T cell receptor (TCR) T cell therapies at Celularity's 37,000 square foot Florham Park, NJ facility. The agreement covers all aspects of cell therapy manufacturing, including Chemistry, Manufacturing and Controls (CMC), Quality Assurance, and Quality Control. BSB will maintain oversight of its second cell therapy product for treating Acute Myelogenous Leukemia (AML) in the U.S. and internationally.
The partnership aims to provide BSB with affordable clinical advancement opportunities while maintaining process control, utilizing Celularity's technical capabilities and manufacturing infrastructure.
The MASS Coalition has welcomed President Trump's order to freeze regulatory guidance not yet in effect, including Medicare Local Coverage Determinations (LCDs) for skin substitute products. The freeze extends until at least April 13, 2025, allowing for further evaluation and public comment.
This decision particularly benefits Medicare beneficiaries with diabetic foot ulcers and venous leg ulcers, ensuring continued access to treatments that help prevent sepsis and amputations. The Coalition criticized the previous administration's LCD implementation process, stating it was conducted without proper stakeholder consultation and could create a healthcare crisis for diabetics by causing treatment shortages.
Celularity (Nasdaq: CELU) has successfully regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Q3 2024 10-Q report. The company had faced listing compliance issues due to delayed filings of Q1 and Q2 2024 reports. To address these challenges, Celularity has implemented significant improvements to its financial reporting infrastructure, including engaging EisnerAmper LLP as its independent audit firm and enhancing internal controls. The resolution ensures the company's continued listing on the Nasdaq Capital Market.
Celularity (NASDAQ: CELU) has filed its Q3 2024 Form 10-Q, becoming current with quarterly report filings. The company reported significant growth in financial performance:
- Total net revenues reached $36.1 million for the nine months ended September 30, 2024, up 238.6% from $10.7 million in the same period last year
- Q3 2024 total net revenues were $9.3 million, increasing 145.5% from $3.8 million in Q3 2023
- Product sales showed exceptional growth, reaching $26.2 million for the nine months ended September 30, 2024, a 621.1% increase from $3.6 million in the previous year
The company has addressed its Nasdaq listing compliance issues by filing the Q3 Form 10-Q and is implementing improvements to ensure timely financial disclosures.
Celularity (Nasdaq: CELU) received a notification from Nasdaq on November 21, 2024, stating non-compliance with listing requirements due to delayed filing of Q3 2024 Form 10-Q. The notice doesn't immediately affect the company's stock listing on Nasdaq Capital Market. Celularity must submit a compliance plan by January 20, 2025, and if accepted, has until May 13, 2025, to implement it. The filing delay stems from a backlog related to previous quarterly filings. The company expects to file Q3 Form 10-Q shortly and has implemented improvements to its financial reporting infrastructure.
Celularity (CELU) announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in Bali, Indonesia. The facility will use Celularity's placenta-derived stem cells manufactured in their US facility. Operations are expected to start by late 2026. The Asia Pacific stem cell market is valued at $3.0 billion (2024) with projected growth to $7.2 billion by 2030 at a 16.4% CAGR. Future plans include initiating onsite manufacturing operations under Celularity's technical supervision.
Celularity Inc. (CELU) has resolved its Nasdaq listing compliance matter after curing its filing delinquency. The company had previously received notification of non-compliance with Nasdaq Listing Rule 5250(c)(1) due to delayed quarterly reports for March and June 2024. Celularity successfully filed both outstanding Form 10-Q reports by November 7, 2024, achieving compliance and ensuring continued listing on Nasdaq. The filing delays were attributed to financial challenges in the biotech sector affecting access to capital and audit services. The company has implemented improvements including engaging EisnerAmper LLP as its independent auditor and enhancing internal controls.
FAQ
What is the current stock price of Celularity (CELUW)?
What is the primary focus of Celularity Inc?
How does Celularity generate revenue?
What innovative approaches are employed by Celularity in its therapies?
What distinguishes Celularity's cell therapy products?
In which market segments does Celularity operate?
What role does the bio-banking segment play for Celularity?
How is Celularity positioned within the regenerative medicine industry?
How does Celularity ensure the quality of its therapies?
